ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

Articles By Prabhat Kumar Saha

Natco-Bayer Verdict

Bayer has lost its case challenging the grant of India's first-ever compulsory licence to Natco Pharma to manufacture an affordable generic version of an anti-cancer drug, but the celebratory air has to be tempered. The issue of what constitutes "local working" of a patent in India remains, in general, unsettled. This article looks at the legality of local working requirements under the Agreement on Trade-related Aspects of Intellectual Property Rights. It also analyses the interpretations of "working" by the Controller General of Patents, Designs and Trademarks, the Intellectual Property Appellate Board, and the Bombay High Court, and considers their broader implications.

Compulsory Licence for Diabetes Drug

This article examines the legality of the Indian pharmaceutical company Lee Pharma's application for compulsory licence for Saxagliptin (Onglyza and Kombiglyze), an anti-diabetes drug, the patent for which is held by the Swedish multinational company AstraZeneca. What are the merits of the prima facie view taken by the controller of patents and the possibility of Lee Pharma getting the licence under the Indian patents law?